PGC-1α reduces Amyloid-β deposition in Alzheimer's disease: Effect of increased VDR expression

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Alzheimer's disease (AD) is characterized by amyloid-β (Aβ) plaques, which suppress vitamin D receptor (VDR) expression, leading to neurodegeneration.
• The precise mechanisms of AD onset and prevention remain largely unknown.
• Peroxisome proliferator-activated receptor-γ coactivator (PGC-1α) is a VDR coactivator that protects cells from oxidative stress, making it a potential therapeutic target for AD.

Purpose of the Study:

• To investigate the role of PGC-1α in Alzheimer's disease (AD).
• To elucidate the specific involvement of VDR in PGC-1α-mediated neuroprotection.
• To explore PGC-1α as a therapeutic strategy for AD.

Main Methods:

• Studied PGC-1α and VDR molecular variations in 6-month-old APP/PS-1 double transgenic (2xTg-AD) mice.
• Utilized a Dlx5/6-Cre:PGC-1α^fl/fl mouse line to specifically assess PGC-1α deficiency in the hippocampus and cortex.
• Employed adeno-associated virus (AAV) to overexpress PGC-1α in the hippocampus of 2xTg-AD mice.

Main Results:

• A significant reduction in PGC-1α and VDR expression was observed in the hippocampus and cortex of 2xTg-AD mice.
• PGC-1α deficiency led to decreased VDR expression and increased oxidative damage in AD-related brain regions.
• Overexpression of PGC-1α in 2xTg-AD mice markedly increased VDR levels, reduced Aβ plaque expression, and decreased 8-oxo-dG (oxidative damage marker).

Conclusions:

• Reduced PGC-1α and VDR expression are implicated in the pathogenesis of Alzheimer's disease.
• PGC-1α plays a crucial neuroprotective role in AD by upregulating VDR and mitigating oxidative stress.
• Targeting PGC-1α overexpression presents a promising therapeutic avenue for Alzheimer's disease.